Communiqués Roche Holding AG

Actions

ROG

CH0012032048

Produits pharmaceutiques

Marché Fermé - Swiss Exchange Autres places de cotation 17:31:20 13/06/2025			Varia. 5j.	Varia. 1 janv.
269,70 ^CHF	-1,06%		+0,56%	+5,56%

00:39	Le médicament expérimental contre l'obésité d'Eli Lilly montre une perte de poids de plus de 11 % lors des premiers essais	RE
13/06	Bourse Zurich: le SMI reste dans le rouge à l'approche de la mi-journée	AW

Communiqués

Genentech’s Tecentriq Combined with Lurbinectedin Shows Significant Survival Benefit in Extensive-Stage Small Cell Lung Cancer	02/06	BU
New Data Show Genentech’s Itovebi Significantly Extended Survival in a Certain Type of HR-positive Advanced Breast Cancer	31/05	BU
Genentech’s Fenebrutinib Maintains Near-Complete Suppression of Disease Activity and Disability Progression for up to Two Years in People With Relapsing Multiple Sclerosis	30/05	BU
New Two-year Follow-up of Genentech’s Columvi Extends Overall Survival in Relapsed or Refractory Diffuse Large B-cell Lymphoma Patients	23/05	BU
FDA Approves Genentech’s Susvimo for Diabetic Retinopathy	22/05	BU
Genentech Provides Update on FDA Advisory Committee Meeting on Columvi Combination for People With Relapsed or Refractory Diffuse Large B-cell Lymphoma	20/05	BU
Ten-Year APHINITY Data Show Genentech’s Perjeta-based Regimen Reduced the Risk of Death by 17% in HER2-Positive Early-Stage Breast Cancer	13/05	BU
Roche and Genentech Announce New North Carolina Manufacturing Facility	12/05	BU
New England Journal of Medicine Publishes Phase III Data Showing Single-dose Xofluza Significantly Reduces Influenza Virus Transmission	25/04	BU
Roche : Q1 2025 Presentation with appendix (irp250424)	24/04	PU
Roche : Q1 2025 Presentation (irp250424 a)	24/04	PU
Swiss pharma giant Roche to invest $50 billion in US, creating 12,000 jobs	22/04	AQ
Genentech and Roche Present Novel Therapeutic and Diagnostic Advancements in Alzheimer’s at AD/PD 2025	03/04	BU
Genentech Provides Update on Phase III Ocrevus High Dose Study in People With Relapsing Multiple Sclerosis	02/04	BU
FDA Accepts Supplemental Biologics License Application for Genentech’s Gazyva for the Treatment of Lupus Nephritis	05/03	BU
FDA Approves Genentech’s TNKase® in Acute Ischemic Stroke in Adults	03/03	BU
Phase III Study Shows Xolair May Be More Effective With Fewer Side Effects Than Oral Immunotherapy for the Treatment of Food Allergies	02/03	BU
FDA Approves Genentech’s Evrysdi Tablet as First and Only Tablet for Spinal Muscular Atrophy (SMA)	12/02	BU
New England Journal of Medicine Publishes New Data for Genentech’s Gazyva Which Shows Superiority Over Standard Therapy in People With Active Lupus Nephritis	07/02	BU
New England Journal of Medicine publishes new data for Roche’s Gazyva/Gazyvaro which shows superiority over standard therapy in people with active lupus nephritis	07/02	AQ
FDA Approves Genentech’s Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes-Related Blindness	04/02	BU
Roche receives FDA approval for the first companion diagnostic to identify patients with HER2-ultralow metastatic breast cancer eligible for ENHERTU	31/01	AQ
Roche : Annual Report 2024 (ar24e)	30/01	PU
Roche : Full-Year 2024 Presentation (irp250130 a)	30/01	PU
Change to the Roche Enlarged Corporate Executive Committee	29/01	AQ